Company news
PTC Therapeutics, Inc. news in 2019
PTC Therapeutics, Inc.'s news releases, calls and decks from 2019, newest first.
PTC Therapeutics Announces FDA Grants Priority Review to Risdiplam for the Treatment of Spinal Muscular Atrophy
November 24, 2019
PTC Therapeutics Launches A No-Cost Testing Program to Drive AADC Deficiency Patient Identification
November 17, 2019
PTC Therapeutics Reports Third Quarter 2019 Financial Results and Provides a Corporate Update
October 28, 2019
PTC Therapeutics Announces Results from Long-Term AADC Deficiency Gene Therapy Treatment Demonstrating Sustained Improvements
October 23, 2019
PTC Therapeutics Establishes Strategic Collaboration with Aldevron to Support GMP Plasmid Manufacturing
October 6, 2019
PTC Therapeutics Announces New Real-World Analysis Demonstrating Translarna(TM) (ataluren) Slows Disease Progression in Patients with Duchenne Muscular Dystrophy
October 3, 2019
PTC Therapeutics Announces Pricing of Private Offering of Convertible Senior Notes
September 17, 2019
PTC Therapeutics Announces Proposed Public Offering of Common Stock
September 16, 2019
PTC Therapeutics Reports Second Quarter 2019 Financial Results and Provides a Corporate Update
August 5, 2019
PTC Therapeutics Announces Strategic Gene Therapy Licensing Agreement with Odylia Therapeutics
June 30, 2019
PTC Provides Update on Translarna(TM) (ataluren) Application for Label Expansion
June 27, 2019
PTC Therapeutics Receives FDA Approval for the Expansion of the EMFLAZA® (deflazacort) Labeling to Include Patients 2-5 Years of Age
June 6, 2019
PTC Therapeutics Reports First Quarter 2019 Financial Results and Provides a Corporate Update
May 1, 2019
Translarna(TM) (ataluren) is the First Therapy Approved in Brazil for Duchenne Muscular Dystrophy
April 28, 2019
PTC Therapeutics to Host Conference Call to Discuss First Quarter 2019 Financial Results
April 17, 2019
Decks in 2019
- 2019 JP Morgan Healthcare Conference
Conference · 39 slides · Jan 7, 2019